GSK welcomes the publication of the 2012 Access to Medicines Index

GlaxoSmithKlineGSK welcomes the publication of the third Access to Medicines (ATM) Index, which measures the performance of the top 20 pharmaceutical companies on their efforts to improve access to medicines and healthcare in developing countries. GSK has been ranked top of the Index in 2012 for the third time of publishing, scoring highest in four categories including general access to medicine management, research and development activity, capability advancement and drug donation and philanthropy.

Commenting on the 2012 Index, GSK CEO Sir Andrew Witty said: "GSK's ranking in the ATM Index is a great acknowledgement of our commitment and to the work and dedication of people throughout GSK - whether the people working to manufacture the millions of doses of vaccines we ship to developing countries, those researching new treatments for diseases such as malaria, dengue and TB or our staff on the ground in Africa who help deliver greater access to medicines every day.

"Enabling greater access to medicines is firmly at the heart of our business. We are determined to do all we can to use our resources, knowledge and expertise to help improve people's health and well-being no matter where in the world they live. We aim to do this while generating the returns we need to sustain our business and invest in further research.

"Over the past five years, this has led us to make fundamental changes to our business model - to ensure our medicines and vaccines are as available and affordable as possible, to encourage more research into neglected diseases, to support communities to strengthen their local health infrastructure and to form partnerships with governments, NGOs and other companies to help amplify our efforts.

"We recognise there is more we can do, and we will continue to challenge ourselves to adopt and deliver new ideas and approaches to improve lives around the world."

The Access to Medicines Index is a major initiative of the Access to Medicines Foundation, an international not-for-profit organisation, established in 2004 and dedicated to improving access to medicines. The index ranks individual pharmaceutical companies on their efforts to enhance global access to medicines across seven categories: drug donation and philanthropy, capability advancement, patents and licensing, equitable pricing, research and development, public policy, and general access to medicines management.

The Index - the first of which was published in 2008, followed by a second in 2010 - provides an overall ranking of 20 pharmaceutical companies who are measured across a range of strategic and technical areas. It also analyses industry trends in commitments, transparency, performance and innovation.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Most Popular Now

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...